ReviewGynecologic oncology2018
Too many women are dying from cervix cancer: Problems and solutions.
Review in Gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Molecular Biomarkers of Radiosensitivity and Radioresistance in Cervical Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Bibliometric analysis: a study of the microenvironment in cervical cancer (2000-2024).Frontiers in oncology · 2025Pooled it
- Case Report: A case of right ventricular metastasis from cervical cancer presenting with thrombocytopenia: the role of echocardiography and myocardial contrast echocardiography.Frontiers in oncology · 2026Article
- Stakeholders' perspectives on lessons learnt from HPV mass vaccination in Nigeria.BMC public health · 2025Article
- Cervical cancer prediction using machine learning models based on routine blood analysis.Scientific reports · 2025Article
- A Proposed mHealth Intervention to Address Patient Barriers to Colposcopy Attendance: Qualitative Interview Study of Clinic Staff and Patient Perspectives.JMIR formative research · 2025Article
- Mechanisms Underlying the Therapeutic Effects ofInternational journal of genomics · 2025Article
- The immediate risk of cancer and its precursor lesions in women with abnormal cervical glandular cytology.Journal of Cancer · 2025Article
- Association of HOTAIR rs7958904 Polymorphism with Cervical Cancer Risk.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Circ_TMCO3 Inhibits the Progression of Cervical Cancer by Activating FRMD6 Expression by Restraining miR-1291.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Article
- Cervical cancer management in a low resource setting: A 10-year review in a tertiary care hospital in Kenya.Gynecologic oncology reports · 2024Article
- Analysis of cancer-associated fibroblasts in cervical cancer by single-cell RNA sequencing.Aging · 2023Article
- Inequities in Screening and HPV Vaccination Programs and Their Impact on Cervical Cancer Statistics in Romania.Diagnostics (Basel, Switzerland) · 2023Article
- How endocervicoscopy can impact obstetric outcomes in women undergoing LEEP for CIN2 + : a retrospective cohort analysis.Archives of gynecology and obstetrics · 2023Article
- Review
- Association of dietary intake and cervical cancer: a prevention strategy.Infectious agents and cancer · 2023Article
- E2F Transcription Factor 1 Activates FKBP Prolyl Isomerase 4 to Promote Angiogenesis in Cervical Squamous Cell Carcinoma Via the PI3K/AKT Signaling Pathway.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Correlation of INHBA Overexpression with Pathological Features, Antitumor Immune Response and Clinical Prognosis in Cervical Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Bone morphogenetic protein signaling is a possible therapeutic target in gynecologic cancer.Cancer science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
One woman dies from cervix cancer every 2 min, adding up to over 270,000 deaths globally per year. This cancer affects a young population, and hence, the loss of life is staggering. There are many aspects of prevention, screening, and care that are suboptimal. A great deal is known about HPV induced carcinogenesis, yet clinical outcomes have been stagnant over decades. There has been no improvement in cervix cancer survival in the US since the mid-1970s [1]. With increased knowledge of the disease and greater worldwide resources including prevention, screening, and improved therapeutics, there is significant promise for fewer women to die from this virally induced cancer. We focus here on the major problems in prevention, screening, and delivery of care for cervix cancer and provide concrete solutions. With appropriate focus, a major improvement in survival from cervix cancer could be achieved in a short time span.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.